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SRRBM20 is a nuclear protein which regulates alternative splicing of expressed genes that have a key
role in cardiac function. By cloning the human and mouse RBM20 cDNA, producing expressing vec-
tors for truncated proteins, and comparing their sub-cellular distribution in transfected cells, we
have identiﬁed the sequences necessary for RBM20 full nuclear retention. The region overlaps an
RNA binding motif and a serine–arginine domain. The sequence is conserved in many species but
belongs only to RBM20 orthologs. The RMB20 tissue speciﬁcity, together with the properties of its
nuclear localization determinant, demonstrates a speciﬁc evolutionary selection of post-transcrip-
tional regulation factors.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction cofactors Raver1 and Raver2 [4–6]. Both SR and hnRNPs proteinsAlternative splicing of the pre-mRNA represents the principal
molecular engine that generates the highly dynamic human prote-
ome through networks of coordinated splicing events [1]. Master
regulators of alternative splicing belong principally to two protein
families: the serine/arginine-rich proteins (SR proteins), and the
heterogeneous nuclear ribonucleoproteins (hnRNPs). Typical SR
proteins bind to enhancers of exon splicing and activate constitu-
tive and alternative splice sites by recruiting spliceosomal compo-
nents to the pre-mRNA and enhancing exon recognition. SF2/ASF
(Splicing Factor 2/Alternative Splicing Factor) and SC35 are the best
known SR proteins [2]. HnRNPs preferentially bind silencers and
inﬂuence constitutive and alternative splicing. One of the most
investigated repressors of exon recognition is the polypyrimidine
tract-binding protein (PTB) [3]. We have previously characterized
the regulatory region required for PTB gene expression and for itsare structurally organized in modular domains represented by
one ormore RNA recognitionmotifs (RRMs), plus additional protein
motifs required for nucleic acids or protein–protein interactions
and subcellular localization [7,8]. In heart and skeletal muscle,
alternative splicing plays a critical role in muscle function [9,10].
RBM20 is a trans-acting factor expressed preferentially in the
heart tissue. The protein has been recently described as a regulator
of alternative splicing of transcripts directly involved into cardiac
function, such as the diastolic function, sarcomere assembly, and
ion transport [11–14]. RBM20 mutations have been found in 3%
of patients diagnosed for familial dilated cardiomyopathy (DCM)
[12,15–19]. The RBM20 protein contains a prototypical RRM, an
arginine/serine-rich region (RS) and U1 zinc ﬁnger domains (ZF)
[15]. A speciﬁc issue of investigation regarding SR proteins is re-
lated to their post-transcriptional regulation, in terms of subcellu-
lar localization and presence of dominant nuclear retention signal
(NRS) [20]. Here we demonstrated that RBM20 contains a region
necessary for its exclusive nuclear localization that overlaps the
RRM and RS domains.
2. Materials and methods
2.1. Bioinformatic analysis
Theexon–intronstructureof thehumanRBM20genewasdeduced
by MGAlignIt (http://origin.bic.nus.edu.sg/mgalign/mgalignit) [21].
ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/index.html) was
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to RBM20 (GenBank ID: NP_001127835) with a selection of RRM do-
mains for which the structure has been determined.
2.2. Cell culture and transfection
Adherent HeLa cells, human embryonic kidney 293 T cells (HEK
293T), human RD (rhabdomyosarcoma cells), and C2C12 mouse
myoblast cell lines were maintained in exponential growth in Dul-
becco’s modiﬁed Eagles medium (DMEM) (Cambrex), supple-
mented with 10% fetal bovine serum (FBS, Cambrex), glutamine
(2.0 mM), penicillin (100 U/L), and streptomycin (100 mcg/L). The
human SK-N-BE neuroblastoma cell line was sub-cultured in RPMI
1640 medium (Cambrex) supplemented with 15% FCS, glutamine
(2.0 mM), and gentamycin sulfate (50 lg/lL). All cell lines were
maintained at 37 C in the presence of 5% CO2. Cells 80% conﬂuent,
were transfected with 2 lg of plasmid DNA using Polyfect reagent
(Qiagen) according to the manufacturer’s instructions. After 24 h,
cells were analyzed by ﬂuorescence microscopy or harvested and
proteins extracted for Western blotting analysis.
2.3. Plasmid construction
RNA was extracted from myocardial tissue biopsy of surgical
patients, and from mouse myoblast cells, C2C12, using TRIzol
reagent (Invitrogen). RNA samples were converted to complemen-
tary DNA (cDNA) by reverse transcription using SuperScript III re-
agents (Invitrogen). Human and mouse RBM20 transcripts were
obtained by polymerase chain reaction (PCR) with primer hF1
and hR1 (Table 1), relative to the human RBM20 sequence GenBank
ID: NM_001134363, position 446–465 and 3739 to 3715, respec-
tively; and primer mF1 and mR1, relative to the mouse Rbm20
sequence, GenBank ID: NM_001170847, position 1–19 and 3594
to 3571, respectively. Human and mouse RBM20 cDNAs were
inserted into the Vivid Colors™ EmGFP TOPOMammalian Expres-
sion Vector kits (Invitrogen), C-terminal to the Emerald Green
Fluorescent Protein A series of RBM20 GFP fused expressingTable 1
Primer pairs used for PCR, cloning and deletion mutations.
Primer name Positiona
Human RBM20
hF1 446 to 465
hF2 1811 to 1830
hF3 1529 to 1548
hF4 1880 to 1900
hF5 2036 to 2053
hF6 1826 to 1850
hR1 3739 to 3715
hR2 2019 to 2001
hR3 2032 to 2012
hR4 1900 to 1881
hR5 1939 to 1917
hR6 1867 to 1847
hR7 1825 to 1805
F DRYK 1820 to 1858
R DRYK 1858 to 1820
F DKK 1841 to 1876
R DKK 1876 to 1841
Mouse RBM20
mF1 1 to 19
mF2 1456 to 1476
mF5 1677 to 1697
mR1 3594 to 3571
mR2 1476 to 1456
mR3 1947 to 1927
a Position are relative to nucleotides numeration sequence refer
NM_001170847 (mouse).constructs was generated by PCR, using the cloned full length
cDNAs as templates and the primers as listed in Table 1. All
expressing vectors were checked for the correct insertion of the
fragments by sequencing at the BMR Genomics facility (http://
www.bmr-genomics.it). Expression and integrity of the proteins
were veriﬁed by Western blotting analysis.
2.4. Reverse transcription polymerase chain reaction (RT-PCR)
Human RBM20 transcript expression analyses were performed
by PCR on Multiple Tissue cDNA panels (MTC™ panel I and II, BD
Biosciences Clontech) representative for adult human tissues [6].
The MTCTM panel I and II consist of ﬁrst-strand cDNAs generated
using oligo-dT primers derived from poly (A)+ RNA isolated from
different human tissues. Forward and reverse hRBM20 speciﬁc
primers hF2 and hR2 (Table 1) were designed based on the se-
quence of the RBM20 mRNA (GenBank ID: NM_001134363).
These were complementary to sequences overlapping RBM20
exons, seven and nine. Forward 50-TGAAGGTCGGAGTCAACG-
GATTTGGT-30 and reverse 50-CATGTGGGCCATGAGGTCCACCAC-30
primers speciﬁc to the glyceraldehydes-3-phosphate dehydroge-
nase (GAPDH) sequence were used in control analyses for the
expression of a housekeeping gene. Murine cDNA samples were
synthesized from total RNA isolated from eight different tissues:
heart, brain, muscle, lung, liver, kidney, colon, stomach. Genomic
DNA was removed and template RNAs were retrotranscribed with
QuantiTect Reverse Transcription kit (Qiagen) by means of ran-
dom examers plus oligo dT. Mouse Rbm20 speciﬁc primers mF5
and mR3 (Table 1) were complementary to sequences of exons
six and eight respectively, derived by mRbm20 GenBank ID:
NM_00117084. Forward 50-CATCTTGGGCTACACTGAGG-30 and re-
verse 50-AGAGTGGGAGTTGCTGTTGA-30 primers, speciﬁc to mur-
ine GAPDH sequences, were used as the internal control of gene
expression. Aliquots of each ampliﬁed product taken after 26,
30, 34 cycles, respectively, were analyzed by electrophoresis on
2.5/5% agarose gels and visualized by SYBR Safe DNA gel stain
(Invitrogen).Primer sequence
50-TCCCAGCCTCTCTTCAATCA-30
50-AAGTTGCTCATTCGGATGTC-30
50-GCAAGGTCATTCACTCAGTC-30
50-GCCATCATCCAGGACATCCAT-30
50-AGCCCTCCGGGCCCCTCC-30
50-ATGTCCAAGAGATACAAGGAATTGC-30
50-GAGCTTTTTCCTTTCGAAGCGTGGC-30
50-GAGGTGAAGCTGGGAGTGT-30
50-GGAAGAGCTGCAGGAGGTGAA-30
50–ATGGATGTCCTGGATGATGG-30
50-TCTGTCTGCTTCCCGGAACATGT-30
50-CCCGGGTTTCTTGAGCTGCAA-30
50-CCGAATGAGCAACTTCTCAC-30
50-ATTCGGATGTCCAAGGAATTGCAGCTCAAG-30
50-CTTGAGCTGCAATTCCTTGGACATCCGAAT-30
50-AAGGAATTGCAGCTCCCCGGGAAGGCCGTG-30
50-CACGGCCTTCCCGGGGAGCTGCAATTCCTT-30
50-GTGCTGGCAGTAGCCATGA-30
50-TATGCAGCCATTCCAACGAG-30
50-CTTGGAGATGGCTTACACAG-30
50-TAGCTTCTTCCTTTCCAAGTGTGG-30
50-CCTCGTTGGAATGGCTGCATA-30
50-ATGGGATCTTGGGGAGAGTG-30ATGGGATCTTGGGGAGAGTG
ence Rbm20 mRNA GenBank ID: NM_001134363(human) and
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HeLa cells were seeded onto sterile glass coverslips and ﬁxed
with 4% paraformaldehyde, permeabilized in acetone and covered
with a blocking solution (2% BSA and 0.3% Triton-X 100 in phos-
phate-buffered saline). The coverslips were then incubated with
anti SC35 (mouse monoclonal SC-35, Abcam) or rabbit PTB primary
antibody, a kind gift from D.L. Black., and a secondary antibodies
for 1 h at room temperature. For nuclear staining, cells were incu-
bated in 0.1–1 lg/ml Hoechst or DAPI for 1 min in the dark..
Images were taken by confocal laser-scanning microscopy
(DM6000B Leica Microsystems GmbH Wetzlar,) with a Leica
DC500 digital camera.
2.6. Immunoblot analysis
Cells were lysed with 0.1 ml of ice-cold lysis buffer: 1% Triton
X-100, 10 mM Tris, pH 7.5,5 mM EDTA pH 8, 150 mM sodium
chloride, 1 tablet/10 ml of Complete Mini EDTA-free proteinase
inhibitor cocktail (Roche Diagnosis GmbH). Proteins were loaded
onto 4–20% gradient SDS–polyacrylamide gels, separated by elec-
trophoresis and transferred onto PVDF membranes. Immobilized
peptides were incubated with rabbit IgG anti GFP antibody (Santa
Cruz Biotechnology diluted 1:500), and then incubated with goat
IgG anti rabbit HRP (Horseradish Peroxidase) labeled antibody
(SIGMA, 1:10000). To detect endogenous RBM20 protein, immo-A
B
Fig. 1. Human RBM20 gene organization. (A) Exon–intron structure of human RBM20 g
First and stop codons are indicated (ATG⁄ is relative to the open reading frame of the card
ClustalW and manually optimized. RNP1 and RNP2, conserved ribonucleoprotein motifsbilized peptides from cellular extracts were incubated with goat
polyclonal anti RBM20 antibody (Abnova, diluted 1:400), and
incubated with donkey anti-goat HRP antibody (Santa Cruz Bio-
technology, diluted 1:4000). Detection was performed using ECL
Advance Western blotting detection kit (GE Healthcare). Images
were taken by a CCD camera, Gel PRO Analyzer (UVP BioImaging
Systemd).
3. Results and discussion
3.1. RBM20 gene organization and predicted protein domains
The human RBM20 gene maps to chromosome 10q25.2 (Gen-
Bank ID: NG_021177) and is organized in 14 exons, which are
expected to encode a protein of 1227 amino acids (GenBank ID:
NP_001127835). From both, the genomics information and the
mRNA sequence (GenBank ID: NM_001134363), we derived a
map of exon–intron boundaries of the RBM20 gene by the MGAl-
ignIt algorithm. A graphical representation of the gene organiza-
tion and functional domains of the translated product, derived by
previously reported annotations [12] and alignments with
homologous domains, are represented in Fig. 1A. The protein
displays three functional domains from which the relative resi-
due positions have been predicted by homology alignments with
conserved domains: a RRM domain represented by residues
519–589, an RS domain at residues 628–655, and a Zn2+ ﬁngerene was deduced by MGAlign using GenBank ID: NM_001134363 and NG_021177.
iac isoform). (B) Multiple sequences alignment of RRM domains were generated by
.
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Fig. 2. RBM20 transcript expression patterns in human and mouse tissues. (A) Expression of human RBM20 in human adult tissues. Poly(A) + RNA were analyzed by PCR
ampliﬁcation using RBM20 speciﬁc primer pairs. M, molecular weight marker. + and  represent PCR reaction with or without added template provided by the systems as
positive control, respectively. (B) Differential expression of Rbm20 in mouse adult tissues. Poly(A) + RNA were analyzed by PCR ampliﬁcation using RBM20 speciﬁc primer
pairs. M, molecular weight marker.  represent PCR reaction without added template. (C) Differential expression of human RBM20 in human cell lines: poly(A) + RNA
extracted from HeLa, RD, SK-N-BE and HEK293T cell lines were analyzed by PCR ampliﬁcation using RBM20 speciﬁc primer. M, molecular weight marker.  represent PCR
reaction without added template. (D) Western blot analysis of human RBM20 expression in HeLa and SK-N-BE cell lines.
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alignment between human RBM20 domains and selected RRMs,
for which the structure has been solved, shows that the highest
degree of homology is shared with the RNP1 consensus sequence
present in the RRM1 belonging to the splicing factor PTB, and its
homolog nPTB (Fig. 1B). RBM20 protein domains are well
conserved in all orthologous reported in the genomes browsers
represented by the common ancestor of chordates, including
cow, rat, mouse, chimpanzee, chicken, and zebra ﬁsh.GFP-mRbm20 SC35 
GFP-mRbm20 PTB A 
B 
Fig. 3. Co-localization of RBM20. The GFP ﬂuorescence in GFP-Rbm20 transiently express
A) or SC35 (red, panel B) was determined by indirect Immunoﬂuorescence, using corresp
localization of the proteins is indicated by yellow in the merged image. DNA was staine3.2. RBM20 gene expression shows a tissue-speciﬁc pattern
In order to assess the tissue speciﬁcity of RBM20 gene expres-
sion, we compared the RBM20 transcript expression, detected by
RT-PCR on panels of poly (A)+ RNA derived from different human
and mouse tissues, as described in Section 2. Human RBM20 tran-
scripts were detected as clear bands in the heart and, in addition, in
skeletal muscle tissues, ovary, small intestine, and colon (Fig. 2A).
Tissue speciﬁcity was also conﬁrmed in mouse tissues, whereDAPI - Merge Merge 
5µm 
DAPI - Merge Merge 
ing HeLa cells was directly visualized (green) and the localization of PTB (red, panel
onding speciﬁc antibodies and analyzed by laser scanning confocal microscopy. Co-
d with DAPI.
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and kidney (Fig. 2B). Similar analyses were performed on RNA de-
rived from human cell lines, i.e. HeLa, RD, SK-N-BE, and HEK 293T.
RBM20 transcripts were not detectable in HeLa cells (Fig. 2D). The
RBM20 protein expression was detected in the human SK-N-BE cell
line by Western blotting using a RBM20 polyclonal antibody
(Fig. 2D). These results demonstrate that RBM20 may be included
into the list of tissue speciﬁc ribonucleoproteins. A few tissue spe-
ciﬁc RNA binding proteins (RBPs) have been demonstrated to be in-
volved in cardiac gene expression and cardiac functionality, such as
the ribonucleoprotein RBM24, expressed abundantly in human
heart tissue and up-regulated during in vitro cardiac differentiation
of human embryonic stem cells [22]. Other additional RBPs have
been proposed to be implicated in heart development and disease,
such as the ETR-3 (elav-like RBPs 3), CELF4 and the general alterna-
tive splicing factor ASF/F2 [23–25].
3.3. Subcellular distribution of RBM20 protein
RBM20 is characterized by two functional domains typical for
splicing factors, the RRM and SR domains. One of the cellular
properties that is attributable to the SR protein behavior is the
speckled nuclear distribution [26]. To analyze the RBM20 intra-
cellular distribution, the cDNA encoding the full length mouse
Rbm20 protein was fused to green ﬂuorescent protein (GFP)
and transiently expressed in HeLa cells. Fluorescence confocal
microscopy analysis showed that GFP-Rbm20 localized
exclusively inside the nucleus. These results are consistent withA
B
C
Fig. 4. RBM20 functional domains required for nuclear localization. (A) Schematic repres
and ZF domains represented as grey boxes). (B) Subcellular localization of wild-type and
and analyzed by confocal microscopy. Nuclei were stained with DAPI. Scale bar = 20 lm.
SR domain.previous data that showed Rbm20 in the nuclei of mouse atrial
myocytes (HL1) and C2C12 cells [12,14]. Rbm20 subnuclear dis-
tribution is characterized by nucleolar exclusion and punctuated
distribution (Fig. 3), a pattern of subcellular distribution that
resembles the nuclear speckles typical of SR proteins [27]. Com-
pared to the endogenous RMB20 distribution shown in previous
studies [12,14], Rbm20 accumulates in many more speckles in
transiently transfected HeLa cells, probably due to the over-
expression of the protein and the differences in the tissues spe-
ciﬁc targets. In order to characterize the nuclear spots of accumu-
lation, we performed a double ﬂuorescence confocal microscopy
analysis. We selected two splicing factors that accumulate in dis-
tinct nuclear complexes involved in splicing processes: the SR
protein SC35 that is representative of the spliceosomal complexes
[2], and the alternative splicing regulator PTB, which accumulates
in the perinucleolar compartment (PNC) [28]. Confocal images of
GFP-Rbm20 transfected cells, visualized Rbm20, SC35, and PTB in
diffused speckles throughout the nucleus (Fig. 3A and B). How-
ever, merged images of GFP-Rbm20 and PTB revealed that only
minor fractions of Rbm20 and PTB co-localized, as indicated by
the arrow (Fig. 3A), whereas co-localization with SC35 was not
visualized (Fig. 3B), as it has been previously demonstrated
[12–14]. In order to test if Rbm20 and PTB were present in the
same cellular complexes, we performed co-immunoprecipita-
tions with antibodies directed against GFP-Rbm20 and PTB, but
PTB was not detectable in the immunocomplexes (supplementary
Fig. 1), indicating that PTB and Rbm20 indicating that PTB and
RBM20 are not associated in the nuclear speckles.entation of human (right column) and mouse (left column) RBM20 protein (RRM, RS
mutant RBM20 proteins. HeLa cells were transfected with the indicated constructs
(C) Alignment of human and mouse sequences containing the RRM domain and the
BA
C
Fig. 5. Effects of deleting RRM, RS region and selected amino acids on the subcellular distribution of RBM20. (A) Analyses of subcellular localization of truncated RBM20
peptides by transient expression. HeLa cells were transfected with the indicated constructs and analyzed by direct ﬂuorescence of GFP protein with confocal microscopy. (B)
Subcellular localization of truncated RBM20 peptides mutated by deletion. HeLa cells were transfected with the indicated mutated constructs and analyzed by direct
ﬂuorescence of GFP protein by confocal microscopy. (C) Schematic plot illustrating the alignment of sequence located between RRM and RS domains of RBM20 protein.
Alignment of conserved region among orthologous RBM20 proteins from different species was obtained by ClustalW2. Protein sequences were obtained from GenBank with
following accession numbers ID: NP_001127835 for human; XP_508032 for chimpanzee; NP_001101081 for rat; NP_001164318 for mouse; XP_421755 for chicken; and
XP_683222 for zebraﬁsh. In the boxes are highlighted amino acids deleted in B.
2994 A. Filippello et al. / FEBS Letters 587 (2013) 2989–29953.4. Effect of deleting domains on the subcellular localization of human
and mouse RBM20
Next, we investigated which domains are required for the nu-
clear distribution of RBM20. We cloned the cDNA containing the
open reading frame for human RBM20 downstream to the GFP se-
quence. The cDNA was obtained from human myocardial tissues
RNA. The open reading frame is relative to a cardiac isoform of hu-
man RBM20 previously reported [12,15], which starts in the exon
2. The alternative ATG is positioned 443 nucleotides far from the
transcription start site (TSS), and represents the second starting
ATG (indicated as ATG⁄ in Fig. A1), whereas the ﬁrst ATG is present
in the exon 1, as reported by sequence in GenBank ID:
NM_001134363. The longer RBM20 isoformwas not detectable un-
der our experimental conditions by RT-PCR in human cardiac tis-
sues. Vectors expressing GFP fused to human (hRBM20), or
mouse RBM20 (mRbm20) were utilized to analyze the contribution
of the protein domains to nuclear distribution. When full length
GFP-RBM20 (human D130–1227 and mouse 1–1199) distribution
was compared to that of truncated peptides deleted for the car-
boxy-terminal end (D130–658), or amino-terminal end up to 486
residue, the intracellular distribution of all expressed peptides
was exclusively nuclear (Fig. 4 panels A and B). Constructs express-
ing RBM20 deleted of both RRM and RS domains (human 658–
1227 and mouse 486–1199) localized exclusively in the cytoplasm
(Fig. 4A and B). Collectively, these results indicate that RBM20 nu-
clear localization requires the region represented by the RRM and
RS domains. The two functional domains are the most conservedbetween human and mouse RBM20, showing 97% positivity for
the RRM domain, and 91% for the RS domain (Fig. 4C).
3.5. RBM20 contains nuclear retention determinants
The results described above promoted us to analyze the contri-
bution of the RRM and/or RS domains to nuclear localization of hu-
man RBM20. Nuclear localization was observed in all transfected
cells with constructs that retained RRM and the sequence up to
residue 614, or both RRM and RS domains (D130–614 and 491–
658 constructs, respectively), whereas the construct containing
the N-terminal up to the RRM without additional residues showed
a nucleus and cytoplasmic distribution (D130–589). Deletion of
RRM impaired the exclusive nuclear localization of construct
608–1227 (Fig. 5A), resulting in a nuclear distribution for approx-
imately 50% of the transfected cells and both, nuclear and cytoplas-
mic for the other 50%. Construct 590–1227 showed a prevalent
nuclear localization, but not in all cells. These results indicate that
RRM alone is not sufﬁcient for nuclear localization but additional
contributions derive by the RS domain and the sequence in be-
tween. In order to determine if the conserved region between
RRM and RS may be necessary for nuclear retention we deleted
separately, selected basic residues between RRM and RS repre-
sented by residues RYK at position 593 (DRYK), and KK residues
at position 600 (DKK). Deletions DRYK and DKK do not modify
the exclusive nuclear localization of the construct 491–658,
whereas the isolated sequence between RRM and RS (590–627)
was not sufﬁcient to direct the GFP protein exclusively to the nu-
A. Filippello et al. / FEBS Letters 587 (2013) 2989–2995 2995cleus (Fig. 5B). These results show that the sequence 491–658 aa,
that includes both RRM and RS, contributes to the full nuclear
localization, thus conﬁrming that this sequence comprises NRSs.
In several SR proteins the RS domain acts as an nuclear localization
signals (NLS), such as SRp20 and SC35 [20,29]. In the case of
RBM20, both RRM and RS domains are required for nuclear reten-
tion. These results support a model for cooperation of RRM and RS
domains of RBM20 in the regulation of its subcellular nuclear local-
ization. We hypothesize that the RRM domain may contribute to
nuclear retention by binding to speciﬁc RNA substrates, as demon-
strated for the titin transcript [14], while an interspaced region and
an RS domain determine the binding to speciﬁc proteins to form a
scaffold that holds the RBM20 protein in the nucleus. Protein–pro-
tein interactions of SR proteins have been previously demonstrated
[30]. A cooperative relationship between RRM and RS domains has
been reported for Psc1 (Peri-implantation stem cell 1), and SF2-ASF
[20,31]. It is interesting to note that the sequence between RRM
and RS is highly conserved between the orthologs, as well as the
RRM and RS, but the similarity is not shared with other SR proteins.
The contribution to a more clear understanding of the functions of
the RBM20 protein domains may help to decipher the complexity
of tissue speciﬁc post transcriptional regulation.
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